BBT-877
- Generic Name
- BBT-877
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
BBT-877 is an autotaxin enzyme inhibitor being investigated for the treatment of fibrotic diseases, such as idiopathic pulmonary fibrosis.
- Associated Conditions
- -
- Associated Therapies
- -
There is a rare disease called idiopathic pulmonary fibrosis (IPF), in which the lungs slowly harden.
Bridge Biotherapeutics, Daewoong, and Ildong Pharmaceutical lead in IPF treatment development, with Bridge's BBT-877 in Phase 2 trials targeting autotaxin. Daewoong's Versiporocin aims to reduce PRS protein action, while Ildong's IL1512 targets CXCR7. Hanmi's HM15211, initially for MASH, shows IPF efficacy. Boehringer Ingelheim's Nerandomilast met primary trial endpoints, but side effects are a concern.
Boehringer seeks approval for lung fibrosis drug following Phase III win
Boehringer Ingelheim seeks approval for nerandomilast after Phase III trial in idiopathic pulmonary fibrosis met primary endpoint. The trial, FIBRONEER-IPF, improved forced vital capacity after 52 weeks. Nerandomilast, a PDE4B inhibitor, received breakthrough therapy designation in 2022 and is also being tested in progressive fibrosing interstitial lung diseases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath